a.) Amendment to the Claims:

- 1. (Original) A prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain which comprises as an active ingredient a compound having an adenosine A_{2A} receptor antagonistic action or a pharmaceutically acceptable salt thereof.
- 2. (Original) The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in Claim 1, wherein the compound having an adenosine A_{2A} receptor antagonistic action is a xanthine derivative.
- 3. (Original) The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in Claim 1, wherein the compound having an adenosine A_{2A} receptor antagonistic action is a xanthine derivative represented by formula (I):

$$\begin{array}{c|c}
R^1 & R^3 \\
 & N & R^4 \\
 & R^2
\end{array}$$
(I)

[wherein R¹, R² and R³ are the same or different, each representing a hydrogen atom, lower alkyl, lower alkenyl or lower alkynyl;

 R^4 represents cycloalkyl, $-(CH_2)_n-R^5$ (in which R^5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4) or formula (II):

$$Y^1$$
 Z
 Y^2
(II)

(wherein Y^1 and Y^2 are the same or different, each representing a hydrogen atom, halogen or lower alkyl; and Z represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group); and X^1 and X^2 are the same or different, each representing an oxygen atom or a sulfur atom].

- 4. (Original) The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in Claim 3, wherein X^1 and X^2 each is an oxygen atom.
- 5. (Currently Amended) The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in Claim 3 or 4 Claim 4, wherein R⁴ is a formula (II):

$$Y^1$$
 Z
 Y^2
(II)

(wherein Y¹, Y² and Z each has the same meanings as mentioned above).

- 6. (Original) The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in Claim 5, wherein Y^1 and Y^2 each is a hydrogen atom.
- 7. (Original) The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in Claim 5 or 6, wherein Z is substituted or unsubstituted aryl or a group represented by formula (III):

$$\begin{array}{c}
O \\ (CH_2)_m \\
O
\end{array}$$
(III)

(wherein R⁶ represents a hydrogen atom, hydroxy, lower alkyl, lower alkoxy, halogen, nitro or amino; and m represents an integer of 1 to 3).

8. (Original) The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in Claim 5 or 6, wherein Z is a group represented by formula (IV):

(wherein at least one of R⁷, R⁸ and R⁹ represents lower alkyl or lower alkoxy and the remaining groups represent a hydrogen atom; R¹⁰ represents a hydrogen atom or lower alkyl)

or formula (III):

$$\begin{array}{c}
O \\ (CH_2)_m \\
O \\
R^6
\end{array}$$
(III)

(wherein R⁶ and m each has the same meanings as mentioned above).

9. (Currently Amended) The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in any of Claims 3 to 8

Claim 5 or 6, wherein R¹ and R² each is ethyl.

- 10. (Currently Amended) The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in any of Claims 3 to 9

 Claim 9, wherein R³ is methyl.
- 11. (Original) The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in Claim 1, wherein the compound having an adenosine A_{2A} receptor antagonistic action is a compound represented by formula (1):

$$H_3CH_2C$$
 N
 N
 N
 N
 CH_2CH_3
 OCH_3
 OCH_3
 OCH_3

12. (Currently Amended) The A method of treating fibromyalgia syndrome comprising administering a therapeutic amount of the prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in any of Claims 1 to 11, wherein the disease accompanied by chronic musculoskeletal pain is fibromyalgia syndrome Claim 11 to a patient in need thereof.

Claim 13 (Cancelled).

- 14. (Currently Amended) The method prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in Claim 13

 Claim 12, wherein the disease relating to fibromyalgia syndrome is one selected from the group consisting of fibrositis, chronic fatigue syndrome, myofascial pain syndrome, diffuse myofascial pain syndrome, generalized fibrisitis, soft tissue rheumatism, non-articular rheumatism, chronic rheumatoid arthritis, primary fibromyalgia syndrome, concomitant fibromyalgia syndrome, idiopathic muscle pain syndrome, chronic widespread musculoskeletal pain, low back pain, Lyme disease accompanied by fibromyalgia syndrome, generalized tendomyopathy, and temporomansibular joint disorder.
- 15. (Currently Amended) A method of preventing and/or treating diseases accompanied by chronic musculoskeletal pain which comprises administering to a patient in need thereof an effective amount of a compound having an adenosine A_{2A} receptor antagonistic action or a pharmaceutically acceptable salt thereof.

Claim 16 (Cancelled).

- 17. (New) The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed Claim 7, wherein R¹ and R² each is ethyl.
- 18. (New) The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed Claim 8, wherein R^1 and R^2 each is ethyl.
- 19. (New) The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in Claim 17, wherein R³ is methyl.
- 20. (New) The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in Claim 18, wherein R³ is methyl.